Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABOSTO:MCAP +3.27%95 Earnings per Share (Diluted) is kr16.00 as of Jun. 2026. GuruFocus rates OSTO:MCAP with a GF Score™ of 95/100 and a GF Value™ of kr572.85 (Fairly Valued). The stock has 1 warning sign investors should review. Among 658 Medical Devices & Instruments companies, MedCap AB ranks better than 74.32% on this metric.
MedCap AB's EPS (Basic) for the
three
months ended in Jun. 2026 was kr4.60.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was kr16.00.
MedCap AB's EPS without NRI for the
three
months ended in Jun. 2026 was kr8.30.
Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was kr18.80.
During the past 12 months, MedCap AB's average EPS without NRIGrowth Rate was 41.40% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 26.50% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 28.80% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 48.70% per year.
During the past 13 years, MedCap AB's highest 3-Year average EPS without NRI Growth Rate was 341.90% per year. The lowest was -71.70% per year. And the median was 30.70% per year.
MedCap AB (OSTO:MCAP) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
MedCap AB Earnings per Share (Diluted) Related Terms
MedCap AB Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for MedCap AB's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MCAP vs ABT, SYK, MDT: Earnings per Share (Diluted) Comparison
For the Medical Devices subindustry, MedCap AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's PE Ratio distribution charts can be found below:
* The bar in red indicates where MedCap AB's PE Ratio falls into.
MedCap AB Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
MedCap AB's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr16.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of kr16.00 mean?
MedCap AB (OSTO:MCAP) has a Earnings per Share (Diluted) of kr16.00 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on MedCap AB and its competitors. According to the industry distribution chart, MedCap AB ranks #169 out of 658 companies in the Medical Devices & Instruments industry, placing it in the top 25.7%.
Is MedCap AB's Earnings per Share (Diluted) too high?
MedCap AB's current Earnings per Share (Diluted) is kr16.00. Based on the distribution chart, MedCap AB ranks #169 out of 658 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MedCap AB has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's Earnings per Share (Diluted) compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #169 out of 658 companies for Earnings per Share (Diluted). This puts MedCap AB in the upper half of its industry. The industry median Earnings per Share (Diluted) is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Devices & Instruments company?
The median Earnings per Share (Diluted) among Medical Devices & Instruments companies is 7.90, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median Earnings per Share (Diluted) is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current Earnings per Share (Diluted) is kr16.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr572.85, compared to a current price of kr568.50 — trading 0.8% below its estimated fair value. The current Earnings per Share (Diluted) is kr16.00. MedCap AB's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current Earnings per Share (Diluted) is kr16.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (OSTO:MCAP) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of kr568.50 is trading 0.8% below its estimated GF Value™ of kr572.85.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for OSTO:MCAP:
Earnings per Share (Diluted): kr16.00
GF Value™: kr572.85 vs. price of kr568.50 (0.8% below fair value)
No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
95GF Score
Get the complete analysis for OSTO:MCAP
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MCAP has been successfully added to your 
